药代动力学
食欲素受体
药理学
医学
食品药品监督管理局
增食欲素
内科学
受体
神经肽
标识
DOI:10.1097/pra.0000000000000672
摘要
This first column in a 2-part series focuses on the pharmacokinetics of the 3 Food and Drug Administration-approved dual orexin receptor antagonists, daridorexant, lemborexant, and suvorexant, specifically as they relate to their use as sleep medications. Although other classes of sleep medications are not discussed, the same pharmacokinetic principles also apply to them.
科研通智能强力驱动
Strongly Powered by AbleSci AI